Anti-Covid vaccine, bilateral agreement between Germany and Biontech for the purchase of 30 million doses outside the European agreements

The Germany has ensured the supply of 30 million doses of Vaccine for COVID-19 through an agreement bilateral with german BioNTech. That is, outside of the agreements signed by European Comission, which through a team of negotiators has concluded in recent months preliminary agreements with the different producers (300 million doses of Pfizer Biontech) on behalf of the 27, to then distribute it to the countries according to the number of inhabitants. The stated objective of Brussels was to supply the product to all Member States “at the same time and under the same conditions“But Berlin has decided to move, too, on its own. To confirm the purchase, the day after the start of the vaccination campaign throughout the EU, was the spokesman for the German Ministry of Health, answering a question during the conference government press in Berlin.

the #EUVaccinationDays they are a moving moment of unity.

The first vaccine was made available to all EU countries:
✔️ at the same time
✔️ under the same conditions

Together we will overcome this pandemic.# Stronger together https://t.co/3EleXUV1Je

– European Comission ???????? (@EU_Commission) December 27, 2020

The Federal Republic, greatly affected by the Second wave of infections that affected health facilities and forced her to emergency shutdown total from December 16 to January 1, in recent weeks I had pressed why the Ema gave the green light to the preparation of Pfizer / BioNTech before Christmas, as it happened later. Also to respond to the controversy over the fact that in U.S me Britain the vaccination campaign started earlier than in the EU.

In addition to asking for additional doses, Germany also aims to step up production on your own soil of the anti-covid-19 vaccine. “We are doing everything together with BioNTech / Pfizer so that there are other production facilities in Germany,” said the German Health Minister. Jens spahn to the issuer Zdf. The objective, he explained, is to start up another production plant Marburg, in the central Land of Hesse. Germany’s BioNTech, based in Mainz, has already taken over the Swiss plant. Novartis, but you have to make some changes before starting production.

Meanwhile, the vaccination campaign in Germany did not start very well: if on Sunday the news came that in at least eight districts of the Bavaria the start-up was postponed due to the interruption of the essential cold chain to keep the properties of the Pfizer preparation intact, today another problem was known. Eight people, all employees of a nursing home, received doses of the Covid-19 vaccine by mistake five times higher than prescribed which is 30 micrograms. They were basically injected the whole vial, which contains precisely 5 doses. Four were subsequently hospitalized and kept under observation after complaining of flu-like symptoms. The others are at home.